Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity
Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer samples. Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased the...
Gespeichert in:
| Veröffentlicht in: | Molecular cancer research Jg. 4; H. 7; S. 437 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.07.2006
|
| Schlagworte: | |
| ISSN: | 1541-7786 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer samples. Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Similar effects on invasion were seen in TLR9-expressing astrocytoma and glioblastoma cells and in the immortalized human breast epithelial cell line MCF-10A. This effect was not, however, dependent on the CpG content of the TLR9 ligands because the non-CpG oligonucleotides induced invasion of TLR9-expressing cells. CpG or non-CpG oligonucleotide-induced invasion in MDA-MB-231 cells was blunted by chloroquine and they did not induce invasion of TLR9(-) breast cancer cells. Treatment of MDA-MB-231 cells with CpG or non-CpG oligonucleotides induced the formation of approximately 50-kDa gelatinolytic band in zymograms. This band and the increased invasion were abolished by a matrix metalloproteinase (MMP) inhibitor GM6001 but not by a serine proteinase inhibitor aprotinin. Furthermore, CpG oligonucleotide treatment decreased tissue inhibitor of metalloproteinase-3 expression and increased levels of active MMP-13 in TLR9-expressing but not TLR9(-) breast cancer cells without affecting MMP-8. Neutralizing anti-MMP-13 antibodies inhibited the CpG oligonucleotide-induced invasion. These findings suggest that infections may promote cancer progression through a novel TLR9-mediated mechanism. They also propose a new molecular target for cancer therapy, because TLR9 has not been associated with cancer invasiveness previously. |
|---|---|
| AbstractList | Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer samples. Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Similar effects on invasion were seen in TLR9-expressing astrocytoma and glioblastoma cells and in the immortalized human breast epithelial cell line MCF-10A. This effect was not, however, dependent on the CpG content of the TLR9 ligands because the non-CpG oligonucleotides induced invasion of TLR9-expressing cells. CpG or non-CpG oligonucleotide-induced invasion in MDA-MB-231 cells was blunted by chloroquine and they did not induce invasion of TLR9(-) breast cancer cells. Treatment of MDA-MB-231 cells with CpG or non-CpG oligonucleotides induced the formation of approximately 50-kDa gelatinolytic band in zymograms. This band and the increased invasion were abolished by a matrix metalloproteinase (MMP) inhibitor GM6001 but not by a serine proteinase inhibitor aprotinin. Furthermore, CpG oligonucleotide treatment decreased tissue inhibitor of metalloproteinase-3 expression and increased levels of active MMP-13 in TLR9-expressing but not TLR9(-) breast cancer cells without affecting MMP-8. Neutralizing anti-MMP-13 antibodies inhibited the CpG oligonucleotide-induced invasion. These findings suggest that infections may promote cancer progression through a novel TLR9-mediated mechanism. They also propose a new molecular target for cancer therapy, because TLR9 has not been associated with cancer invasiveness previously.Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer samples. Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Similar effects on invasion were seen in TLR9-expressing astrocytoma and glioblastoma cells and in the immortalized human breast epithelial cell line MCF-10A. This effect was not, however, dependent on the CpG content of the TLR9 ligands because the non-CpG oligonucleotides induced invasion of TLR9-expressing cells. CpG or non-CpG oligonucleotide-induced invasion in MDA-MB-231 cells was blunted by chloroquine and they did not induce invasion of TLR9(-) breast cancer cells. Treatment of MDA-MB-231 cells with CpG or non-CpG oligonucleotides induced the formation of approximately 50-kDa gelatinolytic band in zymograms. This band and the increased invasion were abolished by a matrix metalloproteinase (MMP) inhibitor GM6001 but not by a serine proteinase inhibitor aprotinin. Furthermore, CpG oligonucleotide treatment decreased tissue inhibitor of metalloproteinase-3 expression and increased levels of active MMP-13 in TLR9-expressing but not TLR9(-) breast cancer cells without affecting MMP-8. Neutralizing anti-MMP-13 antibodies inhibited the CpG oligonucleotide-induced invasion. These findings suggest that infections may promote cancer progression through a novel TLR9-mediated mechanism. They also propose a new molecular target for cancer therapy, because TLR9 has not been associated with cancer invasiveness previously. Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer samples. Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Similar effects on invasion were seen in TLR9-expressing astrocytoma and glioblastoma cells and in the immortalized human breast epithelial cell line MCF-10A. This effect was not, however, dependent on the CpG content of the TLR9 ligands because the non-CpG oligonucleotides induced invasion of TLR9-expressing cells. CpG or non-CpG oligonucleotide-induced invasion in MDA-MB-231 cells was blunted by chloroquine and they did not induce invasion of TLR9(-) breast cancer cells. Treatment of MDA-MB-231 cells with CpG or non-CpG oligonucleotides induced the formation of approximately 50-kDa gelatinolytic band in zymograms. This band and the increased invasion were abolished by a matrix metalloproteinase (MMP) inhibitor GM6001 but not by a serine proteinase inhibitor aprotinin. Furthermore, CpG oligonucleotide treatment decreased tissue inhibitor of metalloproteinase-3 expression and increased levels of active MMP-13 in TLR9-expressing but not TLR9(-) breast cancer cells without affecting MMP-8. Neutralizing anti-MMP-13 antibodies inhibited the CpG oligonucleotide-induced invasion. These findings suggest that infections may promote cancer progression through a novel TLR9-mediated mechanism. They also propose a new molecular target for cancer therapy, because TLR9 has not been associated with cancer invasiveness previously. |
| Author | Rosenthal, Eben Sorsa, Timo Harris, Kevin W Lehtonen, Niko Gehrs, Bradley Merrell, Melinda A Shackley, Brit Selander, Katri S Ilvesaro, Joanna M Chen, Dongquan |
| Author_xml | – sequence: 1 givenname: Melinda A surname: Merrell fullname: Merrell, Melinda A organization: Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, 35294-3300, USA – sequence: 2 givenname: Joanna M surname: Ilvesaro fullname: Ilvesaro, Joanna M – sequence: 3 givenname: Niko surname: Lehtonen fullname: Lehtonen, Niko – sequence: 4 givenname: Timo surname: Sorsa fullname: Sorsa, Timo – sequence: 5 givenname: Bradley surname: Gehrs fullname: Gehrs, Bradley – sequence: 6 givenname: Eben surname: Rosenthal fullname: Rosenthal, Eben – sequence: 7 givenname: Dongquan surname: Chen fullname: Chen, Dongquan – sequence: 8 givenname: Brit surname: Shackley fullname: Shackley, Brit – sequence: 9 givenname: Kevin W surname: Harris fullname: Harris, Kevin W – sequence: 10 givenname: Katri S surname: Selander fullname: Selander, Katri S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16849519$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kEtPwzAQhH0ooqXwE0A-cUux40ecI6p4SZW4lHPkOJvK4NjFdir67wmicNqd0bej0V6gmQ8eELqmZEWpUHdUcFpUlZKrwcSCyIIQUs3Q4t-fo4uU3gkpCa3kOZpTqXgtaL1Au21wrnD2A3AEA_scIq6x3gVvU054H8MQMmADzo1OR2z9QScbPG6P024iTMrv8KBztF94gKydC9NVBut1AqxNtgebj5forNcuwdVpLtHb48N2_VxsXp9e1vebwnAmcsHaTjHCZduTknPJQDPO6tYIJVjX0463JTO8N7QXbUkVAcWkUl1vKtN1UvblEt3-5k4dPkdIuRls-mmvPYQxNVJJITjhE3hzAsd2gK7ZRzvoeGz-XlN-A264ac0 |
| CitedBy_id | crossref_primary_10_1007_s00262_008_0459_8 crossref_primary_10_1038_s41598_025_08960_w crossref_primary_10_3390_cells13020124 crossref_primary_10_1016_j_vetimm_2023_110611 crossref_primary_10_1111_iej_12043 crossref_primary_10_1155_2012_716564 crossref_primary_10_1007_s00262_011_1085_4 crossref_primary_10_1016_j_imlet_2009_10_002 crossref_primary_10_3389_fimmu_2014_00330 crossref_primary_10_1080_0886022X_2019_1591998 crossref_primary_10_1016_j_clml_2013_02_003 crossref_primary_10_1517_14728214_2012_679929 crossref_primary_10_1038_sj_bjc_6605558 crossref_primary_10_1155_2013_293296 crossref_primary_10_1186_1471_2407_10_665 crossref_primary_10_3390_ijms20184506 crossref_primary_10_3389_fimmu_2021_676082 crossref_primary_10_1016_j_leukres_2015_01_002 crossref_primary_10_1007_s12272_009_2100_6 crossref_primary_10_3390_cancers16152679 crossref_primary_10_3892_or_2014_3095 crossref_primary_10_1371_journal_pone_0092748 crossref_primary_10_2217_imt_13_24 crossref_primary_10_1016_j_cellsig_2014_07_035 crossref_primary_10_1177_0961203308100512 crossref_primary_10_1002_jcp_21548 crossref_primary_10_1016_j_canlet_2012_01_040 crossref_primary_10_1038_sj_onc_1210904 crossref_primary_10_2217_bmm_2019_0030 crossref_primary_10_4236_oji_2013_33018 crossref_primary_10_1016_j_chembiol_2015_06_021 crossref_primary_10_1038_icb_2010_75 crossref_primary_10_1517_13543784_2011_553187 crossref_primary_10_1159_000545527 crossref_primary_10_1371_journal_pone_0104398 crossref_primary_10_1186_1471_2407_10_415 crossref_primary_10_1007_s13277_012_0416_1 crossref_primary_10_1186_1755_8794_1_51 crossref_primary_10_1111_jcmm_16214 crossref_primary_10_1111_j_1600_0625_2007_00638_x crossref_primary_10_1111_j_1600_0625_2010_01064_x crossref_primary_10_1186_1750_1172_8_2 crossref_primary_10_1371_journal_pone_0034080 crossref_primary_10_1007_s00262_014_1518_y crossref_primary_10_1002_pros_21115 crossref_primary_10_1007_s00418_008_0466_z crossref_primary_10_1007_s00018_011_0864_6 crossref_primary_10_1039_c2jm16903g crossref_primary_10_1007_s12253_018_0544_z crossref_primary_10_1016_j_intimp_2020_107202 crossref_primary_10_1007_s12253_019_00611_6 crossref_primary_10_1111_j_1600_0714_2010_00929_x crossref_primary_10_1038_onc_2008_171 crossref_primary_10_3389_fimmu_2024_1418025 crossref_primary_10_1371_journal_pone_0051423 crossref_primary_10_1111_apm_12016 crossref_primary_10_2119_molmed_2013_00010 crossref_primary_10_1186_1756_9966_30_84 crossref_primary_10_1111_j_1600_0897_2009_00712_x crossref_primary_10_15252_emmm_202012476 crossref_primary_10_1158_1078_0432_CCR_06_2531 crossref_primary_10_1080_2162402X_2014_1002726 crossref_primary_10_1007_s12253_009_9162_0 crossref_primary_10_1016_j_semnephrol_2015_08_004 crossref_primary_10_1007_s10549_016_3683_5 crossref_primary_10_1016_j_semnephrol_2015_08_005 crossref_primary_10_1038_s12276_020_00540_4 crossref_primary_10_1007_s10549_008_9982_8 crossref_primary_10_1016_j_ajpath_2014_12_011 crossref_primary_10_1038_s41392_021_00687_0 crossref_primary_10_1111_j_1365_2559_2011_03991_x crossref_primary_10_1016_j_cancergencyto_2009_03_006 crossref_primary_10_1371_journal_pone_0183832 crossref_primary_10_1038_onc_2013_302 crossref_primary_10_1158_1078_0432_CCR_07_0603 crossref_primary_10_1007_s00259_019_04607_x crossref_primary_10_1016_j_ijpharm_2016_10_007 crossref_primary_10_1016_j_jns_2016_07_046 crossref_primary_10_1016_j_oooo_2020_01_001 crossref_primary_10_3892_mmr_2014_2839 crossref_primary_10_1016_j_omtn_2021_06_016 crossref_primary_10_1016_j_yexcr_2010_05_024 crossref_primary_10_3390_cells12010152 crossref_primary_10_1177_0961203309356455 crossref_primary_10_4137_CGM_S24314 crossref_primary_10_1016_j_jocn_2011_03_037 crossref_primary_10_3892_or_2017_5941 crossref_primary_10_1002_jcp_21417 crossref_primary_10_2147_CMAR_S305452 crossref_primary_10_1016_j_archoralbio_2011_01_010 crossref_primary_10_1007_s12032_011_9885_0 crossref_primary_10_1002_pros_20562 crossref_primary_10_1007_s10549_011_1590_3 crossref_primary_10_1007_s11523_012_0213_1 crossref_primary_10_3892_ol_2013_1204 crossref_primary_10_1016_j_bbcan_2012_10_006 crossref_primary_10_3892_ol_2013_1602 crossref_primary_10_1089_cbr_2009_0686 crossref_primary_10_1002_jcp_22157 crossref_primary_10_1093_carcin_bgn149 crossref_primary_10_3892_ol_2014_2095 crossref_primary_10_2174_0929867328666210811145043 crossref_primary_10_3390_ijms17050726 crossref_primary_10_1007_s12272_012_0802_7 crossref_primary_10_1111_j_1365_3083_2009_02262_x crossref_primary_10_2165_11316930_000000000_00000 crossref_primary_10_1093_procel_pwad028 crossref_primary_10_1111_j_1349_7006_2010_01491_x crossref_primary_10_1002_med_21480 crossref_primary_10_1007_s10534_010_9305_5 crossref_primary_10_1007_s12307_009_0022_y crossref_primary_10_1080_2162402X_2018_1505174 crossref_primary_10_1007_s10549_013_2762_0 crossref_primary_10_1016_j_critrevonc_2010_12_001 crossref_primary_10_1089_cbr_2009_0699 crossref_primary_10_1016_j_ymthe_2020_12_026 crossref_primary_10_1186_1756_9966_29_92 crossref_primary_10_1371_journal_pone_0010850 crossref_primary_10_1007_s10549_012_2181_7 crossref_primary_10_3389_fonc_2021_628138 crossref_primary_10_3390_ijms22147446 crossref_primary_10_1016_j_cellimm_2016_12_005 crossref_primary_10_1186_s13045_021_01191_2 crossref_primary_10_1016_j_molimm_2021_12_007 crossref_primary_10_1007_s00262_010_0931_0 crossref_primary_10_1002_pbc_24211 crossref_primary_10_1038_s41392_024_01765_9 crossref_primary_10_3892_ol_2011_276 crossref_primary_10_1111_jop_12160 crossref_primary_10_1371_journal_pone_0008474 crossref_primary_10_3390_biom10020249 crossref_primary_10_1093_abbs_gmy104 crossref_primary_10_1158_1541_7786_MCR_07_2005 crossref_primary_10_1002_mc_20325 crossref_primary_10_3390_medicina59101878 crossref_primary_10_1097_MOG_0b013e3282f0153b crossref_primary_10_1371_journal_pone_0131699 crossref_primary_10_1126_scitranslmed_3001510 crossref_primary_10_1016_j_jss_2010_05_038 crossref_primary_10_1016_j_cca_2023_117725 crossref_primary_10_1016_j_yexmp_2015_11_015 crossref_primary_10_3390_ijms242316887 crossref_primary_10_1016_j_urolonc_2014_09_016 crossref_primary_10_1038_nrrheum_2012_106 crossref_primary_10_1016_j_ymthe_2018_02_018 crossref_primary_10_1038_bjc_2012_589 crossref_primary_10_1177_0300060517728634 crossref_primary_10_3892_mmr_2019_10853 crossref_primary_10_1007_s11033_009_9620_5 crossref_primary_10_1007_s12016_015_8497_4 crossref_primary_10_1089_vim_2016_0103 crossref_primary_10_1016_j_biopha_2023_115766 crossref_primary_10_1007_s00262_009_0771_y crossref_primary_10_1111_jop_12272 crossref_primary_10_1111_j_1745_7254_2008_00711_x crossref_primary_10_1186_1471_2407_13_219 crossref_primary_10_1097_CMR_0b013e3283090031 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1541-7786.mcr-06-0007 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| ExternalDocumentID | 16849519 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 123 18M 2FS 2WC 34G 39C 3O- 53G 5RE 5VS AAJMC ABEFU ACGFO ACPRK ADBBV ADCOW AENEX AFFNX AFHIN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 H13 HH5 H~9 IH2 KQ8 L7B MVM NPM OK1 QTD RCR RHF RHI TR2 W8F WHG WOQ X7M YKV ZGI 7X8 |
| ID | FETCH-LOGICAL-c435t-3bd83046bf024463ea3439bc5853df1d4b23c4fc1f5b2180e83688dfc7cdd66f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 199 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000239215300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1541-7786 |
| IngestDate | Thu Sep 04 16:57:41 EDT 2025 Wed Feb 19 01:50:41 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c435t-3bd83046bf024463ea3439bc5853df1d4b23c4fc1f5b2180e83688dfc7cdd66f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 16849519 |
| PQID | 68655404 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_68655404 pubmed_primary_16849519 |
| PublicationCentury | 2000 |
| PublicationDate | 2006-07-01 |
| PublicationDateYYYYMMDD | 2006-07-01 |
| PublicationDate_xml | – month: 07 year: 2006 text: 2006-07-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular cancer research |
| PublicationTitleAlternate | Mol Cancer Res |
| PublicationYear | 2006 |
| SSID | ssj0020176 |
| Score | 2.2886927 |
| Snippet | Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 437 |
| SubjectTerms | Antibodies - pharmacology Astrocytoma - enzymology Astrocytoma - pathology Breast Neoplasms - enzymology Breast Neoplasms - pathology Cell Line, Tumor Collagenases - immunology Collagenases - metabolism CpG Islands DNA-Binding Proteins - genetics Glioblastoma - enzymology Glioblastoma - pathology Humans Matrix Metalloproteinase 13 Matrix Metalloproteinase 8 - metabolism Matrix Metalloproteinase Inhibitors Matrix Metalloproteinases - metabolism Neoplasm Invasiveness Oligonucleotides - genetics Oligonucleotides - pharmacology Toll-Like Receptor 9 - agonists Toll-Like Receptor 9 - biosynthesis Toll-Like Receptor 9 - genetics Toll-Like Receptor 9 - metabolism |
| Title | Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/16849519 https://www.proquest.com/docview/68655404 |
| Volume | 4 |
| WOSCitedRecordID | wos000239215300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB6qVfHio77qcw9e12a7eWxBECkWLy1FKvRWspvdUrRptbXYf-9MkvYmHryEsBBINrMz3zw_gFsTGBULq3jUiAPuI6DlStiIGyUCrdH9CROdkU1EnY7q9xvdEtyvemGorHKlEzNFnUwMxchrIXVQ-p7_MP3gxBlFudWCQGMDyhKBDB3LqL_OIaBly6jlECMITlPSiv4dEajaeu2u3XzJCn88L_odY2a2prX_v7c8gL0CY7LHXCgOoWTTCmznrJPLCuy0i3z6EQx7KAb8ffRmGWo-O0UHnDVYPJzQPN0Zm2a1epZRdJ_KVdkoXcQUXmN6ifcEOCnUwMY05_-bje2c0vjZ6IdRiuaRUdcEkVMcw2vrqdd85gX1AjeIn-Zc6kRRzlQ7tOF-KG0sEblog86FTJxIfF2XxndGuEAjSPCskqFSiTORSZIwdPUT2EwnqT0DFvuB56RWFq2xj96qDpwNhJMywoXIqircrLZygKJNXxSndvI1G6w2swqn-d8YTPMJHAMRKnTsROP8z2cvYDcPmlCB7SWUHR5qewVbZjEfzT6vM4nBa6fb_gEkzcx- |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toll-like+receptor+9+agonists+promote+cellular+invasion+by+increasing+matrix+metalloproteinase+activity&rft.jtitle=Molecular+cancer+research&rft.au=Merrell%2C+Melinda+A&rft.au=Ilvesaro%2C+Joanna+M&rft.au=Lehtonen%2C+Niko&rft.au=Sorsa%2C+Timo&rft.date=2006-07-01&rft.issn=1541-7786&rft.volume=4&rft.issue=7&rft.spage=437&rft_id=info:doi/10.1158%2F1541-7786.MCR-06-0007&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1541-7786&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1541-7786&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1541-7786&client=summon |